Cargando…
Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology
Although nanomedicines have been in the oncology field for almost three decades with the introduction of doxil, only a few nanomedicine products have reached approval. Can nanotechnology be a realistic tool to reduce the number of hospital beds? At present, several clinically approved anti-PD-1/PD-L...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Royal Society
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006034/ https://www.ncbi.nlm.nih.gov/pubmed/35425626 http://dx.doi.org/10.1098/rsos.211991 |